<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04664816</url>
  </required_header>
  <id_info>
    <org_study_id>Omega3-NMIBC</org_study_id>
    <nct_id>NCT04664816</nct_id>
  </id_info>
  <brief_title>Omega-3 Polyunsaturated Fatty Acids and Non-Muscle Invasive Bladder Cancer</brief_title>
  <official_title>Chemopreventive Effect of Omega-3 Polyunsaturated Fatty Acids on the Recurrence of Non-Muscle Invasive Bladder Cancer: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that omega-3 polyunsaturated fatty acids (n-3 PUFAs) might have&#xD;
      a role in prevention of the recurrence of non-muscle invasive bladder cancer (NMIBC).&#xD;
&#xD;
      The patients who are suffering from high-risk NMIBC will be randomly allocated into two&#xD;
      groups: The first group (n-3 PUFAs group): 55 patients will receive omega-3 plus twice daily&#xD;
      for one year after transurethral resection of bladder tumor (TURBT). The second group&#xD;
      (Control group): 55 patients will receive placebo twice daily for one year after TURBT.&#xD;
&#xD;
      All patients will receive intravesical Bacillus Calmette-Guérin (BCG) immunotherapy and they&#xD;
      will be followed up for two years.&#xD;
&#xD;
      The chemopreventive effect of n-3 PUFAs on the recurrence of NMIBC after TURBT will be&#xD;
      studied via magnetic resonance imaging (MRI), inpatient cystoscopy, histopathological&#xD;
      examination and molecular studies of the resected bladder tissues.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesize that omega-3 polyunsaturated fatty acids (n-3 PUFAs) might have&#xD;
      a role in prevention of the recurrence of non-muscle invasive bladder cancer (NMIBC).&#xD;
&#xD;
      The patients who are suffering from high-risk NMIBC will be randomly allocated into two&#xD;
      groups: The first group (n-3 PUFAs group): 55 patients will receive omega-3 plus (1200 mg)&#xD;
      orally, twice a day for at least 12 months. The treatment will start after transurethral&#xD;
      resection of bladder tumor (TURBT), as soon as the histopathology will be obtained. The&#xD;
      treatment will be discontinued if recurrence develops, unacceptable or serious adverse events&#xD;
      occur or according to the patients' request. The second group (Control group): 55 patients&#xD;
      will receive placebo twice daily for one year after TURBT. Patients and care providers will&#xD;
      be blinded to the medication given.&#xD;
&#xD;
      All patients will receive intravesical Bacillus Calmette-Guérin (BCG) immunotherapy and they&#xD;
      will be followed up for two years.&#xD;
&#xD;
      The chemopreventive effect of n-3 PUFAs on the recurrence of NMIBC after TURBT will be&#xD;
      studied via magnetic resonance imaging (MRI), inpatient cystoscopy, histopathological&#xD;
      examination and molecular studies of the resected bladder tissues.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first recurrence.</measure>
    <time_frame>2 years</time_frame>
    <description>Time to first recurrence is defined as the length of time from surgery to the first bladder recurrence or until last follow up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Recurrence-free survival is defined as the length of time after treatment of non-muscle invasive bladder cancer that the patient survives without any radiological, histopathological, immunohistochemical or molecular evidence of tumor recurrence.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Non-Muscle Invasive Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>n-3PUFAs group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These patients will receive omega-3 plus (1200 mg) orally, twice a day for at least 12 months. The treatment will start after TURBT, as soon as the histopathology will be obtained. The treatment will be discontinued if recurrence develops, unacceptable or serious adverse events occur or according to the patients' request.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>These patients will receive placebo orally, twice a day for at least 12 months. The treatment will start after TURBT, as soon as the histopathology will be obtained. The treatment will be discontinued if recurrence develops, unacceptable or serious adverse events occur or according to the patients' request.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>n-3PUFAs Treatment</intervention_name>
    <description>Omega-3 plus (1200 mg) orally, twice a day for at least 12 months.</description>
    <arm_group_label>n-3PUFAs group</arm_group_label>
    <other_name>Treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Treatment</intervention_name>
    <description>Placebo orally, twice a day for at least 12 months.</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Patients who are at high risk for recurrence of NMIBC after TURBT based on the following&#xD;
        tumor characteristics:&#xD;
&#xD;
          -  Stage Ta (G3, multifocal, or ≥ 2 occurrences within 12 months, including the current&#xD;
             tumor),&#xD;
&#xD;
          -  Stage T1 (any grade) and/or,&#xD;
&#xD;
          -  Carcinoma in situ (CIS),&#xD;
&#xD;
          -  Without any indication for radical cystectomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Patients with:&#xD;
&#xD;
          -  ≥ T2 bladder cancer,&#xD;
&#xD;
          -  Evidence of nodal metastasis,&#xD;
&#xD;
          -  Associated upper tract urothelial carcinoma (UTUC) or&#xD;
&#xD;
          -  Those who refuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Elkashef</last_name>
    <role>Principal Investigator</role>
    <affiliation>Urology and Nephrology Center, Mansoura University, Egypt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hassan Abol-Enein</last_name>
    <role>Study Director</role>
    <affiliation>Urology and Nephrology Center, Mansoura University, Egypt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed A. Shokeir</last_name>
    <role>Study Chair</role>
    <affiliation>Urology and Nephrology Center, Mansoura University, Egypt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed Elkashef</last_name>
    <phone>+201000428981</phone>
    <email>ahmed-elkashef@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed Fadallah</last_name>
    <phone>+201061729388</phone>
    <email>mohamedfadalah@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Urology and Nephrology Center, Mansoura University</name>
      <address>
        <city>Mansoura</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Elkashef</last_name>
      <phone>+201000428981</phone>
      <email>ahmed-elkashef@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Ahmed Elkashef</investigator_full_name>
    <investigator_title>Assistant Lecturer of Urology, Urology and Nephrology Center, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Non-muscle invasive bladder cancer;</keyword>
  <keyword>Transurethral resection of bladder tumor;</keyword>
  <keyword>Omega-3 polyunsaturated fatty acids.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

